Arvinas and Pfizer announce initial Phase 1b Data from the TACTIVE-U sub-study of Vepdegestrant in combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium Read more
PROTACs oncology market to hit $3.7 billion by 2030 despite lack of approved therapies: GlobalData Read more